Skip to main content

Table 6 Case-control comparison of NAT2 genotypes

From: Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study

  Controls(N = 426) Cases (N = 545)     
NAT2 Genotype (phenotype) n % n % OR CI p q
NAT2*4/*4 (rapid) 19 4.5 42 7.7 1    
NAT2*4/*5(intermediate) 108 25.4 116 21.3 0.49 0.26-0.88 0.021 0.168
NAT2*4/*6 (intermediate) 49 11.5 69 12.7 0.6 0.30-1.16 0.133 0.532
NAT2*4/*7 (intermediate) 4 0.9 13 2.4 1.43 0.43-5.65 0.576 1
NAT2*5/*6 (slow) 106 24.9 130 23.9 0.55 0.29-0.99 0.053 0.318
NAT2*5/*7 (slow) 5 1.2 10 1.8 0.86 0.26-3.10 0.809 1
NAT2*6/*6 (slow) 42 9.9 47 8.6 0.46 0.23-0.92 0.029 0.203
NAT2*6/*7 (slow) 5 1.2 7 1.3 0.56 0.15-2.21 0.394 1
NAT2*5/*5 (slow) 82 19.2 104 19.1 0.58 0.31-1.07 0.086 0.430
NAT2*5/*14 (slow) 1 0.2 0 0 -- -- --  
NAT2*6/*14 (slow) 0 0 1 0.2 -- -- --  
Missing 5   6   -- -- --  
  1. Logistic regression analysis of individual NAT2 genotypes, adjusted for age. NAT2*4/*4 used as reference. OR = odds ratio; CI = 95% confidence intervals for ORs; p = p-value; q = q values for multiple testing adjustment using Holm's method. Overall chi-squared p = 0.25 (likelihood ratio test). Genotypes with 10 or less counts in either group (case or control) were not included in overall test of significance